#2: Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
- VELCADE, thalidomide and dexamethasone improved pre
- and post-stem cell transplantation results compared to thalidomide and dexamethasone -
ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Millennium...
--(BUSINESS WIRE)-- Multiple myeloma is an almost always-fatal blood cancer. But a recent study in the New England Journal of Medicine showed the prescription drug VELCADE increases patients'...
